NCT04901702 - Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Malignant Germ Cell TumorRecurrent Malignant Solid NeoplasmRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Rhabdoid TumorRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRecurrent Wilms TumorRefractory Ewing SarcomaRefractory HepatoblastomaRefractory Malignant Germ Cell TumorRefractory Malignant Solid NeoplasmRefractory NeuroblastomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory RhabdomyosarcomaRefractory Soft Tissue Sarcoma

Interventions

DRUG

Onivyde

Given intravenous on Days 1 and 8

DRUG

Talazoparib

Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6

DRUG

Temozolomide

Given once a day on Days 1-5.

Trial Locations (10)

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta

38105

St. Jude Children's Research Hospital, Memphis

55404

Children's Hospital and Clinics of Minn, Minneapolis

77030

Texas Children's Hospital/ Baylor College of Medicine, Houston

80045

Children's Hospital Colorado, Aurora

94304

Lucille Packard Children's Hospital Stanford, Palo Alto

Unknown

The Hospital for Sick Children, Toronto

CHU Sainte-Justine, Montreal

BC Children's Hospital Research Institute, Vancouver